Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (Redwood-HCM Cohort 4)

Key Points

• To evaluate the efficacy of aficamten in improving cardiac function in patients with symptomatic non-obstructive hypertrophic cardiomyopathy.
• Randomized trial
• Included patients with symptomatic non-obstructive hypertrophic cardiomyopathy
• Assessment of cardiac function as the primary outcome
• Aficamten significantly improved cardiac function compared to placebo
• Primary endpoint met with a notable percentage of patients showing improvement
• P-value indicates statistical significance for the efficacy of aficamten